In:
European Journal of Haematology, Wiley, Vol. 100, No. 3 ( 2018-03), p. 247-256
Abstract:
Nasal‐type extranodal natural killer NK /T‐cell lymphoma ( ENKTCL ) i s a distinct type of non‐Hodgkin lymphoma with poor prognosis. This research aimed to evaluate the efficacy and safety of the GELOXD or P‐ GEMOXD regimens in patients with ENKTCL . Methods Newly diagnosed ENKTCL patients treated with either the GELOXD or the P‐ GEMOXD regimen were identified from three cancer centers between January 2010 and December 2016. Kaplan‐Meier and Cox regression analyses were used to calculate overall survival ( OS ) and progression‐free survival ( PFS ) and to investigate prognostic factors. Results One hundred and eighty‐four cases were identified from three cancer centers. After 1‐5 treatment cycles of GELOXD or P‐ GEMOXD chemotherapy, 155 (84%) patients showed a complete response ( CR ). The 3‐year OS (73.0% vs 38.2%, P = .001) and PFS (72.8% vs 32.4%, P = .000) rates were significantly higher in early‐stage patients compared with advanced‐stage patients. A multivariate analysis revealed that patient CR status was a significant independent factor in disease prognosis. Grade 3/4 leukopenia occurred in 43 (23.4%) patients. Major non‐hematological toxicities included nausea (n = 117, 63.6%) and vomiting (n = 66, 35.9%). Conclusions The GELOXD and P‐ GEMOXD chemotherapy regimens are well tolerated and provide favorable survival outcomes in patients with ENKTCL .
Type of Medium:
Online Resource
ISSN:
0902-4441
,
1600-0609
DOI:
10.1111/ejh.2018.100.issue-3
Language:
English
Publisher:
Wiley
Publication Date:
2018
detail.hit.zdb_id:
2027114-1